Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Control Intervention1: NIL: NIL
Sponsors
Atrimed Biotech LLP
Eligibility
Inclusion criteria
Inclusion criteria: 1) Both male and female adult populations aged from 18 to 60 years with background comorbidities such as Type II Diabetes mellitus(DM), hypertension(HTN), Bronchial asthma, Ischemic heart disease(IHD), cerebrovascular accidents(CVA), Thyroid disorders will be included in the study. 2) Convalescent, RTPCR negative for SARS-CoV2 ( 2 weeks), IgG positive for SARS CoV2 , asymptomatic patients as determined by the principal investigator/ physician. 3) SARS CoV2 frontline workers are included as test subjects. 4) Non health care workers are included as control subjects. 5) Volunteer is willing and able to comply with all the trial requirements. 5) All volunteers obtained written informed consent form in English as well as native language, Kannada
Exclusion criteria
Exclusion criteria: 1) Patients with active COVID-19 infection( PCR positive, IgM positive). 2) Known patients of HIV, Hepatitis-B/C , H1N1. 3) Pregnant and lactating women. 4) Patients with known autoimmune diseases on immuno-suppressants and steroids. 5) Patients who have participated in another clinical trial within the previous 30 days. 6) Patient not willing to give informed consent form
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| COVID-19 T-cell immunity positive or negativeTimepoint: within 1 week of COVID-19 negative PCR test or 3 weeks after COVID-19 active infection | — |
Secondary
| Measure | Time frame |
|---|---|
| Indicator of COVID-19 T-cell immunity in recovered patients and for vaccine efficiencyTimepoint: 4weeks post infection | — |
Countries
India
Contacts
Public ContactDr Hrishikesh Damle
Indoor Biotechnologies India Pvt. Ltd.
Outcome results
None listed